ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 138,95
-0,70%
Dow Jones
39 865,01
0,15%
DAX
18 730,49
-0,19%
Brent Oil
82,915
-0,74%
Bitcoin
70 253,97
-1,67%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. ADC Therapeutics SA (ADCT)

  7. ADC Therapeutics SA (ADCT) Actualités

ADCT

ADC Therapeutics (ADCT)

ADC Therapeutics SA
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:ADCT
DateHeureSourceTitreSymboleSociété
15/05/202413h15GlobeNewswire Inc.ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNYSE:ADCTADC Therapeutics SA
14/05/202418h32Edgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
09/05/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
09/05/202413h15GlobeNewswire Inc.ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare ConferenceNYSE:ADCTADC Therapeutics SA
07/05/202422h06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ADCTADC Therapeutics SA
07/05/202422h02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:ADCTADC Therapeutics SA
06/05/202413h30GlobeNewswire Inc.ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded WarrantsNYSE:ADCTADC Therapeutics SA
06/05/202412h38Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ADCTADC Therapeutics SA
06/05/202412h10GlobeNewswire Inc.ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
06/05/202412h00GlobeNewswire Inc.ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone LymphomaNYSE:ADCTADC Therapeutics SA
01/05/202422h05GlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
01/05/202413h00GlobeNewswire Inc.ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024NYSE:ADCTADC Therapeutics SA
04/04/202413h00GlobeNewswire Inc.ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaNYSE:ADCTADC Therapeutics SA
03/04/202413h00GlobeNewswire Inc.ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024NYSE:ADCTADC Therapeutics SA
13/03/202412h03IH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNYSE:ADCTADC Therapeutics SA
13/03/202412h00GlobeNewswire Inc.ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
06/03/202413h15GlobeNewswire Inc.ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes SummitNYSE:ADCTADC Therapeutics SA
06/03/202413h00GlobeNewswire Inc.ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024NYSE:ADCTADC Therapeutics SA
05/03/202423h45GlobeNewswire Inc.ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual MeetingNYSE:ADCTADC Therapeutics SA
27/02/202413h00GlobeNewswire Inc.ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceNYSE:ADCTADC Therapeutics SA
04/01/202413h15GlobeNewswire Inc.ADC Therapeutics Regains Compliance with NYSE Continued Listing StandardsNYSE:ADCTADC Therapeutics SA
04/01/202413h00GlobeNewswire Inc.ADC Therapeutics Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
03/01/202402h10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
19/12/202313h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:ADCTADC Therapeutics SA
18/12/202322h25Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:ADCTADC Therapeutics SA
12/12/202311h15GlobeNewswire Inc.ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)NYSE:ADCTADC Therapeutics SA
20/11/202308h40PR Newswire (US)Sobi to present new data at ASH 2023 Annual MeetingNYSE:ADCTADC Therapeutics SA
15/11/202309h00GlobeNewswire Inc.Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of DirectorsNYSE:ADCTADC Therapeutics SA
07/11/202313h15GlobeNewswire Inc.ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing StandardsNYSE:ADCTADC Therapeutics SA
07/11/202313h00GlobeNewswire Inc.ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
 Showing the most relevant articles for your search:NYSE:ADCT

Dernières Valeurs Consultées

GATE
EFIUSDT
Efinity Token
AMEX
IBDR
iShares iBonds Dec 2026 ...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés